A Study to Investigate the Safety and Tolerability of a New Inhaled Formulation of RV568 in Healthy Volunteers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Respivert Ltd
ClinicalTrials.gov Identifier:
NCT01661244
First received: August 7, 2012
Last updated: March 1, 2013
Last verified: March 2013

August 7, 2012
March 1, 2013
September 2012
February 2013   (final data collection date for primary outcome measure)
  • Incidence of treatment emergent adverse events [ Time Frame: Cohort 1, 56 days; Cohorts 2 & 3, 28 days; Cohorts 4 & 5, 35 days ] [ Designated as safety issue: No ]
    Assessment of the number of adverse events reported by subjects following dosing.
  • ECG assessment [ Time Frame: Cohort 1, 56 days; Cohorts 2 & 3, 28 days; Cohorts 4 & 5, 35 days ] [ Designated as safety issue: No ]
    Change from pre-dose values.
  • Vital signs assessment [ Time Frame: Cohort 1, 56 days; Cohorts 2 & 3, 28 days; Cohorts 4 & 5, 35 days ] [ Designated as safety issue: No ]
    Change from pre-dose values
  • Spirometry assessment [ Time Frame: Cohort 1, 56 days; Cohorts 2 & 3, 28 days; Cohorts 4 & 5, 35 days ] [ Designated as safety issue: No ]
    Change from pre-dose values
Same as current
Complete list of historical versions of study NCT01661244 on ClinicalTrials.gov Archive Site
Plasma RV568 levels [ Time Frame: Cohorts 1, 2 & 3: Day 1 (0, 15, 30 & 45 min and 1, 2, 4, 6, 8, 10, 12 and 24 h), then 7, 14 and 28 days. Cohorts 4 & 5: Day 1, 7 & 14 (0, 15, 30 & 45 min and 1, 2, 4, 6, 8, 10, 12 and 24 h), Day 10, 11, 12 & 13 (0 & 30 min), then Day 21, 28 and 35 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study to Investigate the Safety and Tolerability of a New Inhaled Formulation of RV568 in Healthy Volunteers
A Randomised, Double-blind, Placebo-controlled, Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV568 in Healthy Volunteers

RV568 is being developed as a possible treatment of smoking related lung disease (also known as Chronic Obstructive Pulmonary Disease - COPD).

The main purpose of this study is to examine the safety and tolerability of a new inhaled formulation of RV568 in healthy volunteers. The study will be run in two parts; Part A and Part B. Part A (Cohorts 1, 2 & 3) will investigate 6 different dose levels of RV568 given as a single dose and Part B (Cohorts 4 & 5) will investigate 2 different dose levels of RV568 given once a day for 14 days.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • COPD
  • Healthy Volunteers
  • Drug: RV568 single dose
    Safety and tolerability of single escalating doses in normal human volunteers
  • Drug: RV568 matching placebo single dose
    Safety and tolerability of escalating repeat doses in normal human volunteers.
  • Drug: RV568 repeat dose
    Safety and tolerability of escalating repeat doses in normal human volunteers.
  • Drug: RV568 matching placebo repeat dose
    Safety and tolerability of escalating repeat doses in normal human volunteers.
  • Experimental: Part A - Single dose escalation
    Interventions:
    • Drug: RV568 single dose
    • Drug: RV568 matching placebo single dose
  • Experimental: Part B - 14 day repeat dose escalation
    Interventions:
    • Drug: RV568 repeat dose
    • Drug: RV568 matching placebo repeat dose
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
February 2013
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent.
  • Healthy as determined by a physician, based on a full medical evaluation including medical history, physical examination, and laboratory tests.
  • Body weight ≥50 kg and body mass index within the range 19-29 kg/m2 (inclusive).
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • Average QTc(B) or QTc(F) <450 msec (or QTc <480 msec in healthy subjects with right bundle branch block).
  • Capable of complying with all study restrictions and procedures including ability to use the Dry Powder Inhaler correctly.
  • Spirometry readings (FEV1 and FVC) to be ≥ 80% predicted value and FEV1/FVC ratio > 0.7 calculated using ECCS reference equations.
  • Vital sign assessments within normal ranges (systolic blood pressure (SBP) 90 140 mm/Hg; diastolic blood pressure (DBP) 55 - 90 mm/Hg; heart rate (HR) 40 - 100 bpm).
  • Agree not to use prescription medications within 14 days before first administration of study medication and through the duration of the study (with the exception of contraception and hormone replacement therapy (HRT)).
  • Agree not to use over the counter (OTC) medications (including corticosteroids, decongestants, antihistamines, aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs)) and herbal medication (including, but not limited to, herbal tea and St. John's Wort), within 14 days before first administration of study medication and through to the final follow up visit, unless approved by the Investigator and Sponsor Medical Monitor. Occasional use of paracetamol at recommended doses (≤ 1 g/ 6 hours and ≤ 2 g/day) and continued pre-existing use of vitamins at recommended doses is allowed.

Exclusion Criteria:

  • Any acute or chronic illness or clinically relevant abnormality identified on the screening medical assessment, laboratory tests or ECG.
  • Upper or lower respiratory tract infection within 4 weeks of the screening visit.
  • A positive pre-study hepatitis B surface antigen or positive hepatitis C antibody result at screening.
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • Positive urinary drugs or breath alcohol test at screening or prior to dosing.
  • The Investigator suspects drug or alcohol abuse.
  • A positive test for human immunodeficiency virus antibody.
  • History of regular alcohol consumption within 6 months of the study.
  • The subject has participated in any other study of an investigational drug during the 3 months before receipt of the first dose of study medication or has previously received RV568.
  • Regular use of prescription or non-prescription drugs within 14 days prior to the first dose of study medication.
  • Allergy to any of the active or inactive ingredients in the study medication.
  • History of drug, or other allergy that, in the opinion of the Investigator or Sponsor Medical Monitor, would contraindicate their participation.
  • The subject is a smoker (regular or irregular), or has smoked or used nicotine-containing products within the 6 months prior to screening.
  • Positive carbon monoxide breath test at the screening visit indicative of smoking or use of tobacco or nicotine-containing products.
  • Donation of blood in excess of 500 mL within a 3 month period prior to screening, or if study participation would result in blood loss in excess of 500 mL in a 3 month period.
  • The subject is unable or unwilling to comply fully with the study protocol.
  • Subject is mentally or legally incapacitated.
  • Subject is an employee of the Sponsor or contract research organization (CRO), or a relative of an employee of the Sponsor or CRO.
  • Unable or unwilling to undergo multiple venepuncture procedures or the subject has poor access to veins suitable for cannulation.
  • A positive pregnancy test or is a lactating (nursing) female.
  • Any other reason that the Investigator considers makes the subject unsuitable to participate.
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT01661244
RVH007
No
Respivert Ltd
Respivert Ltd
Not Provided
Study Director: Dr Garth Rapeport Respivert Ltd
Respivert Ltd
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP